Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.03
MYL's Cash to Debt is ranked lower than
98% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. MYL: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
MYL' s 10-Year Cash to Debt Range
Min: 0.02  Med: 1.83 Max: 44.56
Current: 0.03
0.02
44.56
Equity to Asset 0.41
MYL's Equity to Asset is ranked lower than
79% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MYL: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
MYL' s 10-Year Equity to Asset Range
Min: 0.19  Med: 0.76 Max: 0.92
Current: 0.41
0.19
0.92
Interest Coverage 4.06
MYL's Interest Coverage is ranked lower than
90% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2456.17 vs. MYL: 4.06 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s 10-Year Interest Coverage Range
Min: 0.83  Med: 3.59 Max: 9.19
Current: 4.06
0.83
9.19
F-Score: 6
Z-Score: 2.13
M-Score: -2.17
WACC vs ROIC
7.93%
9.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.16
MYL's Operating margin (%) is ranked higher than
74% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.81 vs. MYL: 16.16 )
Ranked among companies with meaningful Operating margin (%) only.
MYL' s 10-Year Operating margin (%) Range
Min: 2.31  Med: 18.41 Max: 36
Current: 16.16
2.31
36
Net-margin (%) 11.05
MYL's Net-margin (%) is ranked higher than
68% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.92 vs. MYL: 11.05 )
Ranked among companies with meaningful Net-margin (%) only.
MYL' s 10-Year Net-margin (%) Range
Min: -3.53  Med: 14.33 Max: 26.04
Current: 11.05
-3.53
26.04
ROE (%) 19.57
MYL's ROE (%) is ranked higher than
81% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.31 vs. MYL: 19.57 )
Ranked among companies with meaningful ROE (%) only.
MYL' s 10-Year ROE (%) Range
Min: -14.72  Med: 14.19 Max: 29.99
Current: 19.57
-14.72
29.99
ROA (%) 5.17
MYL's ROA (%) is ranked higher than
57% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.19 vs. MYL: 5.17 )
Ranked among companies with meaningful ROA (%) only.
MYL' s 10-Year ROA (%) Range
Min: -2.47  Med: 7.85 Max: 18.43
Current: 5.17
-2.47
18.43
ROC (Joel Greenblatt) (%) 24.36
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. MYL: 24.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.11  Med: 37.69 Max: 92.62
Current: 24.36
4.11
92.62
Revenue Growth (3Y)(%) 11.60
MYL's Revenue Growth (3Y)(%) is ranked higher than
62% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MYL: 11.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.1  Med: 15.55 Max: 54.5
Current: 11.6
-6.1
54.5
EBITDA Growth (3Y)(%) 11.30
MYL's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. MYL: 11.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20  Med: 11.85 Max: 107
Current: 11.3
-20
107
EPS Growth (3Y)(%) 24.20
MYL's EPS Growth (3Y)(%) is ranked higher than
77% of the 452 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.20 vs. MYL: 24.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYL' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.8  Med: 11.80 Max: 110.4
Current: 24.2
-28.8
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MYL Guru Trades in Q3 2014

Ray Dalio 57,106 sh (New)
Paul Tudor Jones 20,015 sh (+376.55%)
Louis Moore Bacon 435,000 sh (+335.00%)
Vanguard Health Care Fund 15,444,880 sh (+223.41%)
John Paulson 12,494,700 sh (+3.00%)
John Hussman 50,000 sh (unchged)
Louis Moore Bacon 350,000 sh (unchged)
Pioneer Investments 282,805 sh (unchged)
Steven Cohen Sold Out
Scott Black 199,406 sh (-1.25%)
Mario Gabelli 10,000 sh (-27.54%)
Jim Simons 465,200 sh (-28.67%)
First Eagle Investment 809,603 sh (-34.81%)
» More
Q4 2014

MYL Guru Trades in Q4 2014

Joel Greenblatt 673,287 sh (New)
Paul Tudor Jones 254,152 sh (+1169.81%)
Pioneer Investments 691,198 sh (+144.41%)
John Paulson 14,948,400 sh (+19.64%)
First Eagle Investment 841,779 sh (+3.97%)
Mario Gabelli 10,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
Jim Simons Sold Out
Vanguard Health Care Fund 15,037,080 sh (-2.64%)
Ray Dalio 52,706 sh (-7.70%)
Scott Black 181,796 sh (-8.83%)
Louis Moore Bacon 36,196 sh (-91.68%)
» More
Q1 2015

MYL Guru Trades in Q1 2015

Tom Russo 5,850 sh (New)
Steven Cohen 253,300 sh (New)
Pioneer Investments 826,251 sh (+19.54%)
Vanguard Health Care Fund 15,891,898 sh (+5.68%)
Scott Black 187,570 sh (+3.18%)
Mario Gabelli 10,000 sh (unchged)
John Paulson 14,948,400 sh (unchged)
Paul Tudor Jones 125,000 sh (unchged)
Ray Dalio Sold Out
John Hussman Sold Out
Louis Moore Bacon Sold Out
First Eagle Investment 586,016 sh (-30.38%)
Paul Tudor Jones 109,447 sh (-56.94%)
Joel Greenblatt 16,021 sh (-97.62%)
» More
Q2 2015

MYL Guru Trades in Q2 2015

Vanguard Health Care Fund 15,891,898 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Mylan NV

Vanguard Health Care Fund Comments on Mylan NV - Mar 27, 2015

We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Mylan NV

Tom Russo Buys 3 New Stocks in Q1
Tom Russo (Trades, Portfolio) added three new stocks to his portfolio during Q1, including an insurance and pharmaceutical company, according to GuruFocus Real Time Picks. Read more...
Vanguard Health Care Fund Comments on Mylan NV
We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.37
MYL's P/E(ttm) is ranked higher than
64% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.20 vs. MYL: 25.37 )
Ranked among companies with meaningful P/E(ttm) only.
MYL' s 10-Year P/E(ttm) Range
Min: 7.05  Med: 23.51 Max: 112.56
Current: 25.37
7.05
112.56
Forward P/E 11.74
MYL's Forward P/E is ranked higher than
88% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. MYL: 11.74 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.40
MYL's PE(NRI) is ranked higher than
64% of the 475 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.00 vs. MYL: 25.40 )
Ranked among companies with meaningful PE(NRI) only.
MYL' s 10-Year PE(NRI) Range
Min: 7.05  Med: 23.67 Max: 200.11
Current: 25.4
7.05
200.11
P/B 2.98
MYL's P/B is ranked higher than
54% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.42 vs. MYL: 2.98 )
Ranked among companies with meaningful P/B only.
MYL' s 10-Year P/B Range
Min: 0.64  Med: 2.67 Max: 7.02
Current: 2.98
0.64
7.02
P/S 2.87
MYL's P/S is ranked higher than
55% of the 653 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. MYL: 2.87 )
Ranked among companies with meaningful P/S only.
MYL' s 10-Year P/S Range
Min: 0.41  Med: 1.83 Max: 4.61
Current: 2.87
0.41
4.61
PFCF 56.40
MYL's PFCF is ranked lower than
60% of the 273 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.64 vs. MYL: 56.40 )
Ranked among companies with meaningful PFCF only.
MYL' s 10-Year PFCF Range
Min: 8.81  Med: 19.69 Max: 88.5
Current: 56.4
8.81
88.5
POCF 22.28
MYL's POCF is ranked higher than
62% of the 385 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.53 vs. MYL: 22.28 )
Ranked among companies with meaningful POCF only.
MYL' s 10-Year POCF Range
Min: 6.09  Med: 12.67 Max: 40.56
Current: 22.28
6.09
40.56
EV-to-EBIT 29.12
MYL's EV-to-EBIT is ranked lower than
56% of the 489 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.18 vs. MYL: 29.12 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s 10-Year EV-to-EBIT Range
Min: -10.7  Med: 16.45 Max: 33
Current: 29.12
-10.7
33
PEG 3.06
MYL's PEG is ranked lower than
53% of the 249 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. MYL: 3.06 )
Ranked among companies with meaningful PEG only.
MYL' s 10-Year PEG Range
Min: 0.45  Med: 2.43 Max: 11.64
Current: 3.06
0.45
11.64
Shiller P/E 42.35
MYL's Shiller P/E is ranked lower than
56% of the 309 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.46 vs. MYL: 42.35 )
Ranked among companies with meaningful Shiller P/E only.
MYL' s 10-Year Shiller P/E Range
Min: 10.98  Med: 25.10 Max: 1402
Current: 42.35
10.98
1402
Current Ratio 1.40
MYL's Current Ratio is ranked lower than
74% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. MYL: 1.40 )
Ranked among companies with meaningful Current Ratio only.
MYL' s 10-Year Current Ratio Range
Min: 1.28  Med: 3.44 Max: 8.52
Current: 1.4
1.28
8.52
Quick Ratio 1.04
MYL's Quick Ratio is ranked lower than
73% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.66 vs. MYL: 1.04 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s 10-Year Quick Ratio Range
Min: 0.85  Med: 2.85 Max: 6.76
Current: 1.04
0.85
6.76
Days Inventory 150.90
MYL's Days Inventory is ranked lower than
68% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.56 vs. MYL: 150.90 )
Ranked among companies with meaningful Days Inventory only.
MYL' s 10-Year Days Inventory Range
Min: 88.95  Med: 147.43 Max: 175.9
Current: 150.9
88.95
175.9
Days Sales Outstanding 104.95
MYL's Days Sales Outstanding is ranked lower than
72% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.45 vs. MYL: 104.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s 10-Year Days Sales Outstanding Range
Min: 49.61  Med: 83.48 Max: 107.26
Current: 104.95
49.61
107.26

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.84
MYL's Price/Projected FCF is ranked higher than
70% of the 297 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.37 vs. MYL: 1.84 )
Ranked among companies with meaningful Price/Projected FCF only.
MYL' s 10-Year Price/Projected FCF Range
Min: 0.62  Med: 1.39 Max: 2.51
Current: 1.84
0.62
2.51
Price/DCF (Earnings Based) 3.24
MYL's Price/DCF (Earnings Based) is ranked lower than
78% of the 51 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. MYL: 3.24 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.56
MYL's Price/Median PS Value is ranked lower than
63% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. MYL: 1.56 )
Ranked among companies with meaningful Price/Median PS Value only.
MYL' s 10-Year Price/Median PS Value Range
Min: 0.36  Med: 1.94 Max: 3.77
Current: 1.56
0.36
3.77
Price/Peter Lynch Fair Value 2.55
MYL's Price/Peter Lynch Fair Value is ranked lower than
61% of the 145 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.01 vs. MYL: 2.55 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.67  Med: 1.55 Max: 10.2
Current: 2.55
0.67
10.2
Earnings Yield (Greenblatt) (%) 3.40
MYL's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. MYL: 3.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3  Med: 5.70 Max: 15.1
Current: 3.4
3
15.1
Forward Rate of Return (Yacktman) (%) 12.45
MYL's Forward Rate of Return (Yacktman) (%) is ranked higher than
64% of the 305 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. MYL: 12.45 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYL' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 3.6  Med: 6.30 Max: 39.2
Current: 12.45
3.6
39.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:0R5P.UK, MYL1.Switzerland, 6MY.Germany,
Mylan NV was incorporated in Pennsylvania in 1970. The Company together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company offers 1,300 marketed products, to customers in 140 countries and territories. It also operates a research and development network that delivers a robust product pipeline. Additionally, the Company has a specialty business that is engaged in the respiratory and allergy therapies. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids while engaging on those products that are difficult to formulate and manufacture, and typically have longer life cycles than traditional generic pharmaceuticals, including transdermal patches, high potency formulations, injectables, controlled-release and respiratory products. In addition, it offers antiretroviral therapies upon which HIV/AIDS patients in developing countries depend. The Company operates in two segments, Generics and Specialty. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages in the development, manufacture and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and have also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
KEELEY All Cap Value Fund First Quarter 2015 Commentary Jun 17 2015 
Actavis Stock – A Must Have For Long-Term Investors May 27 2015 
Tom Russo Buys 3 New Stocks in Q1 May 18 2015 
Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 
Teva Eyeing Mylan For $40 Billion Apr 23 2015 
CalAmp and Illumina Significant Earnings Growth; Perrigo Rebuffs Takeover Offer Apr 22 2015 
Vanguard Health Care Fund Comments on Mylan NV Mar 27 2015 
Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
Gilead Taking Giant Leap To Serve The Hepatitis C Market Of Developing Countries Feb 26 2015 

More From Other Websites
What to Expect from Synta (SNTA) this Earnings Season? - Analyst Blog Aug 03 2015
Will Perrigo (PRGO) Earnings Disappoint Estimates in Q2? - Analyst Blog Aug 03 2015
Will Endocyte (ECYT) Earnings Surprise Investors in Q2? - Analyst Blog Aug 03 2015
The 7 Most Important Earnings in the Week Ahead Aug 02 2015
Teva Proves Its Decade-Hold Status With Massive Funding Jul 31 2015
Mylan Inc. -- Moody's Affirms Mylan's Baa3; outlook changed to negative from developing Jul 31 2015
Mylan Is the Lone Underperformer in IBB’s Top 10 Jul 31 2015
Analysts ask if Mylan can make case with its shareholders for Perrigo purchase Jul 29 2015
Mylan gets EU clearance for Perrigo clearance Jul 29 2015
Mylan gets European clearance in proposed Perrigo takeover Jul 29 2015
Mylan gets European clearance in proposed Perrigo takeover Jul 29 2015
Abbott Laboratories Earnings Analysis: By the Numbers Jul 29 2015
Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of... Jul 29 2015
EU clears acquisition of Perrigo by Mylan Jul 29 2015
More tie-ups in generic drug cos expected Jul 28 2015
Amgen Stock Clears Buy Point Ahead Of Earnings Jul 28 2015
Mylan selloff draws bullish trades Jul 28 2015
There's 'Life After Teva' For Mylan, Says Leerink Jul 28 2015
BMO Ups Teva To Buy; Allergan Deal 'Solidifies Leadership' In Generics Jul 28 2015
Has Mylan Labs Been Stichting it to Shareholders? A Lawsuit Says 'Yes!' Jul 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK